


A2A receptor antagonist 2

Cat. No.:	HY-144672
CAS No.:	2767206-20-0
Molecular Formula:	C ₂₅ H ₂₈ FN ₇ O ₃
Molecular Weight:	493.53
Target:	Adenosine Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	A2A receptor antagonist 2 (Compound 57) is a potent, highly selective adenosine A _{2A} receptor (A _{2A} R) antagonist with an IC ₅₀ of 8.3 nM ^[1] .																
IC₅₀ & Target	A2AR 8.3 nM (IC ₅₀)																
In Vitro	<p>A2A receptor antagonist 2 (Compound 57) shows potent antagonistic activity in the presence of a high level of NECA (5'-N-ethylcarboxamidoadenosine, an A_{2A}R agonist)^[1].</p> <p>A2A receptor antagonist 2 enhances the activation and effector function of T cells, with no obvious cytotoxicity toward the HCT116 cells and MC38 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Jurkat T cells</td> </tr> <tr> <td>Concentration:</td> <td>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>Overnight</td> </tr> <tr> <td>Result:</td> <td>Increased IL-2 production in the presence of NECA</td> </tr> </table> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCT116 and Jurkat T cells</td> </tr> <tr> <td>Concentration:</td> <td>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Completely reversed NECA's suppression of the cytotoxic function of Jurkat T cells.</td> </tr> </table>	Cell Line:	Jurkat T cells	Concentration:	10 μM	Incubation Time:	Overnight	Result:	Increased IL-2 production in the presence of NECA	Cell Line:	HCT116 and Jurkat T cells	Concentration:	10 μM	Incubation Time:	48 h	Result:	Completely reversed NECA's suppression of the cytotoxic function of Jurkat T cells.
Cell Line:	Jurkat T cells																
Concentration:	10 μM																
Incubation Time:	Overnight																
Result:	Increased IL-2 production in the presence of NECA																
Cell Line:	HCT116 and Jurkat T cells																
Concentration:	10 μM																
Incubation Time:	48 h																
Result:	Completely reversed NECA's suppression of the cytotoxic function of Jurkat T cells.																
In Vivo	<p>A2A receptor antagonist 2 (Compound 57) shows reasonable intravenous (IV) exposure and low bioavailabilities of intraperitoneal (IP) and per os (PO)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																

Animal Model:	C57BL/6 mice ^[1]		
Dosage:	2 or 10 mg/kg		
Administration:	Intraperitoneal, intravenous or oral administration (Pharmacokinetic Analysis)		
Result:	PK profiles of A2A receptor antagonist 2 (n = 3) ^[1]		
	Parameters		
	Dosing Route	IV (2 mg/kg)	PO (10 mg/kg) IP (10mg/kg)
	C _{max} (ng/mL)	1091 ± 129 ^a	106 ± 33.0 41.8 ± 2.75
	AUC _{0-last} (ng/mL*h)	767 ± 107	145 ± 25.9 812 ± 12.0
	AUC _{0-t} (ng/mL*h)	764 ± 107	139 ± 25.9 444 ± 13.3
	T _{1/2} (h)	2.05 ± 0.94	2.55 ± 2.39 17.6 ± 0.68
	F (%)	/	3.78% 11.6%
	^a This value means C ₀ = 1091 ± 129 ng/mL		

REFERENCES

[1]. Fazhi Yu, et al. Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. J Med Chem. 2022 Mar 10;65(5):4367-4386.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA